BR112021006968A2 - avexitide para o tratamento da hipoglicemia hiperinsulinêmica - Google Patents

avexitide para o tratamento da hipoglicemia hiperinsulinêmica Download PDF

Info

Publication number
BR112021006968A2
BR112021006968A2 BR112021006968-2A BR112021006968A BR112021006968A2 BR 112021006968 A2 BR112021006968 A2 BR 112021006968A2 BR 112021006968 A BR112021006968 A BR 112021006968A BR 112021006968 A2 BR112021006968 A2 BR 112021006968A2
Authority
BR
Brazil
Prior art keywords
avexitide
individual
administered
formulation
hypoglycemia
Prior art date
Application number
BR112021006968-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Colleen M. Craig
Lisa Porter
Original Assignee
Eiger Biopharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals, Inc filed Critical Eiger Biopharmaceuticals, Inc
Publication of BR112021006968A2 publication Critical patent/BR112021006968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021006968-2A 2018-10-15 2019-10-15 avexitide para o tratamento da hipoglicemia hiperinsulinêmica BR112021006968A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862745915P 2018-10-15 2018-10-15
US62/745,915 2018-10-15
US201862746229P 2018-10-16 2018-10-16
US62/746,229 2018-10-16
US201962823493P 2019-03-25 2019-03-25
US62/823,493 2019-03-25
PCT/US2019/056278 WO2020081534A1 (en) 2018-10-15 2019-10-15 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Publications (1)

Publication Number Publication Date
BR112021006968A2 true BR112021006968A2 (pt) 2021-07-27

Family

ID=70283142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006968-2A BR112021006968A2 (pt) 2018-10-15 2019-10-15 avexitide para o tratamento da hipoglicemia hiperinsulinêmica

Country Status (10)

Country Link
US (1) US20210338780A1 (https=)
EP (2) EP4233842A3 (https=)
JP (2) JP2022513351A (https=)
CN (1) CN112867730A (https=)
AU (2) AU2019359807B2 (https=)
BR (1) BR112021006968A2 (https=)
CA (1) CA3115527A1 (https=)
CL (1) CL2021000892A1 (https=)
IL (2) IL314504A (https=)
WO (1) WO2020081534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271753A1 (en) 2021-06-21 2022-12-29 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
CN121219002A (zh) * 2023-04-21 2025-12-26 小利兰斯坦福大学董事会 Glp-1r拮抗作用改善胃肠外科手术后的营养

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US20160185837A1 (en) * 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
LT3297653T (lt) * 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10653753B2 (en) * 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt) * 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai

Also Published As

Publication number Publication date
WO2020081534A1 (en) 2020-04-23
IL282059A (en) 2021-05-31
AU2019359807A1 (en) 2021-05-13
US20210338780A1 (en) 2021-11-04
EP3867266A1 (en) 2021-08-25
AU2025208421A1 (en) 2025-08-14
CL2021000892A1 (es) 2021-11-12
CA3115527A1 (en) 2020-04-23
JP2025000798A (ja) 2025-01-07
IL314504A (en) 2024-09-01
JP2022513351A (ja) 2022-02-07
EP3867266A4 (en) 2022-07-13
AU2019359807B2 (en) 2025-04-24
EP4233842A2 (en) 2023-08-30
EP4233842A3 (en) 2023-10-25
CN112867730A (zh) 2021-05-28

Similar Documents

Publication Publication Date Title
AU2023237119B2 (en) Buffered formulations of exendin (9-39)
US12220444B2 (en) Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
JP2019535734A5 (https=)
US20130096059A1 (en) Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
AU2025208421A1 (en) Avexitide for the treatment of hyperinsulinemic hypoglycemia
BR112019010236B1 (pt) Formulações tamponadas de exendina (9-39) e uso das mesmas
HK40014636A (en) Buffered formulations of exendin (9-39)
HK40014636B (en) Buffered formulations of exendin (9-39)
BR122025006444A2 (pt) Formulações tamponadas de exendina (9-39)

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: EIGER BIOPHARMACEUTICALS, INC (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870250038403 DE 12/05/2025, E NECESSARIO APRESENTAR DOCUMENTO DE CESSAO COM A ASSINATURA DO REPRESENTANTE DA CEDENTE, VISTO QUE NO DOCUMENTO APRESENTADO NA REFERIDA PETICAO NAO CONSTA TAL ASSINATURA. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: AMYLYX PHARMACEUTICALS, INC. (US)